Novelion Therapeutics Observes World Lipodystrophy Day
31 Março 2019 - 3:00AM
Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical
company dedicated to developing new standards of care for
individuals living with rare diseases, in association with its
subsidiary Aegerion Pharmaceuticals, today announced its observance
of World Lipodystrophy Day. World Lipodystrophy Day is an
international campaign designed to raise awareness about the impact
of living with lipodystrophy.
Interim Chief Executive Officer Ben Harshbarger
said, "We stand with the patient community in honor of World
Lipodystrophy Day with a mission of increasing awareness and
diagnosis of this serious rare disease. Education is an important
step towards making an impact for people affected by lipodystrophy,
many of whom are undiagnosed and inadequately treated.”
Lipodystrophy is a group of rare diseases
characterized by a lack of fat tissue. In some patients, it is
genetic, and in others it may be acquired. It can be characterized
by a widespread lack of fat tissue under the skin (generalized
lipodystrophy) or limited lack of fat tissue (partial
lipodystrophy). This loss of fat tissue causes a deficit in the
hormone leptin leading to multiple medical issues, including severe
metabolic complications.
To learn more about lipodystrophy, visit
https://www.lipodystrophy.eu/, www.lipodystrophyunited.org, and
www.aelip.org.
About Novelion Therapeutics
Novelion, through its subsidiary Aegerion Pharmaceuticals, is a
global biopharmaceutical company dedicated to developing and
commercializing therapies that deliver new standards of care for
people living with rare diseases. With a global footprint and an
established commercial portfolio, including MYALEPT® (metreleptin)
and JUXTAPID® (lomitapide), our business is supported by
differentiated treatments that treat severe and rare diseases.
CONTACT:
Amanda Murphy, Director, Investor Relations
& Corporate CommunicationsNovelion
Therapeutics857-242-5024amanda.murphy@novelion.com
Novelion Therapeutics (NASDAQ:NVLN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Novelion Therapeutics (NASDAQ:NVLN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Novelion Therapeutics Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de